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SUMMARY
It is well-known that obesity causes several disease, especially, cardiovascular disease. The
metabolic syndrome-the cluster of obesity, impaired fasting glucose, elevated triglycerides, low
high-density lipoprotein cholesterol, and hypertension, has been identified as an independent risk
factor for cardiovascular disease. In this syndrome, abdominal obesity play a critical role for de-
velopment of insulin resistance and atherosclerosis. Recently it is reported that visceral fat accu-
mulation brings impaired adipocytokine environment such as increase of inflammatory cytokine
and decrease of adiponectin. On the other hand, adipose tissue has an ability to activate cortisone
that causes steroid excess in peripheral tissue. Though it seems to need some reevaluation, waist
circumference is an useful biomarker for clinical intervention in the metabolic syndrome which
aims to avoid the development of cardiovascular disease.
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